A phase III study of Calmangafodipir (PledOx®) in patients treated adjuvantly for colorectal cancer

Trial Profile

A phase III study of Calmangafodipir (PledOx®) in patients treated adjuvantly for colorectal cancer

Planning
Phase of Trial: Phase III

Latest Information Update: 08 Feb 2018

At a glance

  • Drugs Calmangafodipir (Primary)
  • Indications Chemotherapy-induced damage
  • Focus Registrational; Therapeutic Use
  • Acronyms POLAR-A
  • Sponsors PledPharma
  • Most Recent Events

    • 08 Feb 2018 According to a PledPharma media release, the patients enrollment is expected in second half of 2018.
    • 16 Nov 2017 According to a PledPharma media release, the company intends to initiate the Phase III study before year end 2017 and to have first patient in by early 2018.
    • 03 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top